Form 990 for tax year 2022

Totals

Total revenue

$33,133,692

Total expenses

$32,888,928

Contributions and grants received

$31,125,188

Grants paid

$20,648,632

Program service revenue

$363,476

Investment income

$1,837,688

Other revenue

-$192,660

Total assets, end of year

$98,117,170

Total liabilities, end of year

$14,432,042

Net assets or fund balances, end of year

$83,685,128

Program services expenses (Part IX)

$24,327,020

Management and general expenses

$1,459,960

Fundraising expenses

$7,101,948

Program service expenses (Part III)

$24,327,020

Program services were 74.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2022

• SEE SCHEDULE O:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $158 MILLION IN CANCER RESEARCH GRANTS TO OVER 2,600 RECIPIENTS IN 80 COUNTRIES. HIGHLIGHTS OF 2022 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE:RESEARCH PROFESSORSHIP (RP): $500,000 PROVIDED ONE (1) FIVE-YEAR AWARD TO AN OUTSTANDING RESEARCHER WHO HAS MADE, AND IS CONTINUING TO MAKE, SIGNIFICANT CONTRIBUTIONS IN BREAST CANCER RESEARCH AND WILL DEDICATE THEIR TIME IN TRAINING FUTURE BREAST CANCER RESEARCHERS. THIS PROFESSORSHIP IS DESIGNED WITH THE PRIMARY GOAL OF INCREASING DIVERSITY IN THE LEADERSHIP OF THE ONCOLOGY WORKFORCE AND CANCER RESEARCH. *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $900,000 PROVIDED TWO (2) THREE-YEAR AWARDS TO SUPPORT PHYSICIAN-SCIENTISTS COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS. BOTH AWARDS SUPPORTED DIVERSITY/INCLUSION, FOCUSING ON BREAST CANCER. *CAREER DEVELOPMENT AWARD (CDA): $4,400,000 PROVIDED TWENTY-TWO (22) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH TO CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. *YOUNG INVESTIGATOR AWARD (YIA): $4,820,000 PROVIDED NINETY-SIX (96) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. *GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $291,500 PROVIDED SIX (6) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS.THIS IS A MENTORED AWARD AND THE RESEARCH PROJECT IS CONDUCTED UNDER THE GUIDANCE OF A SCIENTIFIC MENTOR. *INTERNATIONAL INNOVATION GRANT: $94,838 PROVIDED FIVE (5) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO POTENTIALLY DISCOVERING INTERVENTIONS TRANSFERABLE TO CLINICAL CARE IN OTHER LOW OR MIDDLE RESOURCE COUNTRY SETTINGS.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER UTILIZES ITS EXPERTISE IN GRANTS ADMINISTRATION AND PROGRAM MANAGEMENT TO COLLABORATE WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE.

  Expenses $17,585,949 · Grants $14,125,671

• SEE SCHEDULE O:PROFESSIONAL EDUCATION: CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS AND LATEST DEVELOPMENTS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2022 INCLUDE THE FOLLOWING: * ASCO ANNUAL MEETING: THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY WITH MORE THAN 42,000 PARTICIPANTS WORLDWIDE IN 2022. THE ANNUAL MEETING PROVIDES A FORUM TO JOIN GLOBAL CANCER EXPERTS AND DISCOVER THE LATEST INNOVATIONS IN CANCER RESEARCH AND EDUCATION WHILE ADDRESSING THE NEED FOR EVERY PATIENT TO RECEIVE THE HIGHEST QUALITY CANCER CARE AVAILABLE. *GASTROINTESTINAL CANCERS (GI) SYMPOSIUM: THIS IS THE PREMIER MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS. *GENITOURINARY CANCERS (GU) SYMPOSIUM: THIS IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. *QUALITY CARE SYMPOSIUM: THIS IS AN UNPARALLELED OPPORTUNITY TO LEVERAGE THE MOST UP-TO-DATE SCIENCE AND DISCOVER PROVEN STRATEGIES AND TOOLS CRITICAL TO MAKING KEY DECISIONS THAT CAN REDUCE DISPARITIES IN CARE FOR EVERY PATIENT, EVERY DAY, EVERYWHERE. *MERIT AWARDS: 240,000 PROVIDED TWO HUNDRED THIRTY-SIX (236) MERIT AWARDS PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. *MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR): $238,000 PROVIDED TWENTY-EIGHT (28) MEDICAL STUDENT ROTATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER.

  Expenses $5,744,479 · Grants $5,619,139

• SEE SCHEDULE O:QUALITY & ACCESS TO CARE: REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE THAT ARE UNDERSERVED.

  Expenses $996,592 · Grants $903,822 · Revenue $363,476

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• AMERICAN SOCIETY OF CLINICAL ONCOLOGY

  $9,233,468

  CHARITABLE ASSISTANCE

• MEMORIAL SLOAN-KETTERING CANCER CENTER

  $1,250,000

  CDA, YIA

• UT SOUTHWESTERN MEDICAL CENTER

  $950,000

  YIA

• OHIO STATE UNIVERSITY

  $800,000

  ARCA, CDA, YIA

• THE GENERAL HOSPITAL CORP DBA MASSACHUSETTS GENERAL HOSPITAL

  $700,000

  CAREER PATHWAY GRANT IN SYMPTON MANAGEMENT, YIA

• EMORY UNIVERSITY

  $600,000

  CDA

• UNIVERSITY OF CALIFORNIA SAN FRANCISCO

  $550,000

  CDA, YIA

• DANA-FARBER CANCER INSTITUTE INC

  $400,000

  CDA,YIA

• JOHNS HOPKINS UNIVERSITY

  $300,000

  CDA

• WASHINGTON UNIVERSITY IN ST LOUIS

  $300,000

  YIA

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• AMERICAN SOCIETY OF CLINICAL ONCOLOGY

  501(C)(3) · EDUCATION · NY

• ASCO ASSOCIATION

  501(C)(6) · MEMBER SERVICES · VA

  Directly controlled by ASCO

• ASCO ASSOCIATION PAC

  527 · PAC · VA

  Directly controlled by ASCO ASSOCIATION

Provenance

Return type

form_990

Tax year

2022

Filed

26 September 2023

IRS schema version

2022v5.0

Source object

202332719349301118

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.